Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cryoport (CYRX) Research & Development (2016 - 2026)

Cryoport has reported Research & Development over the past 17 years, most recently at $3.9 million for Q1 2026.

  • Quarterly Research & Development fell 0.69% to $3.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $17.0 million through Mar 2026, up 0.72% year-over-year, with the annual reading at $17.0 million for FY2025, 3.78% down from the prior year.
  • Research & Development was $3.9 million for Q1 2026 at Cryoport, down from $4.5 million in the prior quarter.
  • Over five years, Research & Development peaked at $5.2 million in Q3 2023 and troughed at $3.5 million in Q2 2022.
  • The 5-year median for Research & Development is $4.2 million (2024), against an average of $4.3 million.
  • Year-over-year, Research & Development decreased 21.07% in 2022 and then increased 29.28% in 2023.
  • A 5-year view of Research & Development shows it stood at $4.7 million in 2022, then increased by 1.54% to $4.7 million in 2023, then decreased by 12.51% to $4.2 million in 2024, then grew by 7.48% to $4.5 million in 2025, then dropped by 12.52% to $3.9 million in 2026.
  • Per Business Quant, the three most recent readings for CYRX's Research & Development are $3.9 million (Q1 2026), $4.5 million (Q4 2025), and $4.5 million (Q3 2025).